Use the hyperlinks, where available to access additional clinical trial information.
A Randomised Open-label Phase II Trial of Consolidation With Nivolumab and Ipilimumab in Limited-stage SCLC After Chemo-radiotherapy
European Thoracic Oncology Platform
Bristol-Myers Squibb (BMS)
Other Non-Commercial Sponsor
Ludwig Institute for Cancer Research
In this trial, participants will be randomised to the experimental treatment or observation arm. In the experimental arm, participants will receive Nivolumab (1mg/kg IV) and Ipilimumab (3mg/kg IV) as induction therapy once every three weeks for four cycles, followed by 240mg Nivolumab IV as maintenance therapy once every two weeks for a maximum of 12 months.